Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Trial Profile

Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Romidepsin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Peripheral T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Ro-CHOP
  • Most Recent Events

    • 11 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 29 Jun 2017 This trial has been completed in Germany (end date: 10 May 2017).
    • 04 Sep 2015 Planned End Date changed from 1 Jul 2022 to 1 Jul 2024 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top